CIK 0001580063
BIOR BIORA THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing Dec 16, 2024.
BIORA THERAPEUTICS, INC. (BIOR) has 1 SEC Form 4 filing on file from 1 insider, the latest filed on Dec 16, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at BIORA THERAPEUTICS, INC., scored.
Transactions
Every row filed, 1 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2024 | Athyrium Opportunities III Co-Invest 1 LP director, owner | AGrant or award 11.00% / 13.00% Convertible Senior Secured Notes due 2028derivativeindirect: See footnotes | - | - | - | - | Dec 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Athyrium Opportunities III Co-Invest 1 LPdirector, owner
Questions about BIOR
Answered from the filings on this page, as of the latest one.
Are insiders buying BIOR?
No. In the last 90 days no insider at BIORA THERAPEUTICS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade BIOR on the open market?
No open-market trade has been scored at BIORA THERAPEUTICS, INC.. The latest Form 4 on file was filed on Dec 16, 2024 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at BIORA THERAPEUTICS, INC.?
1 person has filed a Form 4 at BIORA THERAPEUTICS, INC., among them Athyrium Opportunities III Co-Invest 1 LP (director and 10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.